Pacer Advisors Inc. Buys Shares of 20,333 Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Pacer Advisors Inc. bought a new stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 20,333 shares of the company’s stock, valued at approximately $1,307,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. FMR LLC increased its holdings in Ionis Pharmaceuticals by 0.6% in the 1st quarter. FMR LLC now owns 20,633,698 shares of the company’s stock valued at $1,674,837,000 after buying an additional 123,948 shares during the period. First Trust Advisors LP boosted its position in Ionis Pharmaceuticals by 16.7% during the 1st quarter. First Trust Advisors LP now owns 2,591,839 shares of the company’s stock worth $210,380,000 after buying an additional 370,977 shares during the period. OppenheimerFunds Inc. boosted its position in Ionis Pharmaceuticals by 0.4% during the 1st quarter. OppenheimerFunds Inc. now owns 2,027,449 shares of the company’s stock worth $164,568,000 after buying an additional 7,323 shares during the period. Renaissance Technologies LLC acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $112,814,000. Finally, Geode Capital Management LLC boosted its position in Ionis Pharmaceuticals by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 1,341,433 shares of the company’s stock worth $72,517,000 after buying an additional 82,152 shares during the period. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have issued reports on IONS. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. ValuEngine lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Piper Jaffray Companies set a $75.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, May 24th. TheStreet lowered shares of Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. Finally, Evercore ISI set a $76.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. Ionis Pharmaceuticals has an average rating of “Hold” and an average target price of $69.00.

Shares of NASDAQ:IONS traded up $0.01 during mid-day trading on Friday, hitting $66.88. The company had a trading volume of 21,550 shares, compared to its average volume of 912,331. The firm has a fifty day moving average price of $65.56 and a 200 day moving average price of $69.43. The company has a market capitalization of $9.41 billion, a PE ratio of 22.61 and a beta of 1.97. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.01 and a quick ratio of 9.93. Ionis Pharmaceuticals Inc has a one year low of $43.27 and a one year high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.26. The company had revenue of $164.00 million during the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. Ionis Pharmaceuticals’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) EPS. Research analysts expect that Ionis Pharmaceuticals Inc will post -0.07 earnings per share for the current fiscal year.

In other Ionis Pharmaceuticals news, CEO Stanley T. Crooke sold 10,000 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $70.25, for a total transaction of $702,500.00. Following the completion of the sale, the chief executive officer now owns 79,634 shares in the company, valued at approximately $5,594,288.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total transaction of $1,573,440.00. Following the sale, the chairman now owns 79,634 shares of the company’s stock, valued at approximately $5,695,423.68. The disclosure for this sale can be found here. Insiders sold a total of 47,210 shares of company stock valued at $3,244,934 in the last quarter. 2.40% of the stock is currently owned by company insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

See Also: What is a Tariff?

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit